Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Status
- WITHDRAWN
- Phase
- PHASE1
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Status
- RECRUITING
- Phase
- PHASE2
Evaluating Novel Therapies in ctDNA Positive GI Cancers
- Status
- RECRUITING
- Phase
- PHASE3
Phase 2 Study of DKN-01 in Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
- Status
- WITHDRAWN
- Phase
- NA